Skip to Content

Few Patients with KRAS-Mutated Tumors Receive Targeted Treatment

According to a recent study conducted by the Phase 1 Unit at the Department of Oncology, Copenhagen University Hospital, over 80% of solid tumors with KRAS mutations were found to have potentially targetable co-alterations. However, the study also revealed that less than 8% of patients with these tumors received treatment based on these findings.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top